Mylan CEO on EpiPen price hike and fixing the system

Published Apr 27 2021 at 2:35 AM GMT
Key
Points
  • Pharmaceutical giant Mylan was at the center of criticism last year over rising drug prices.
  • Its EpiPen became the lightning rod for scrutiny, as the life-saving allergy drug's price increased by nearly 500 percent over seven years.
  • In her first in-depth interview since giving testimony before Congress, Mylan CEO Heather Bresch talks to Norah O'Donnell and responds to the outrage among lawmakers and consumers.




Stats

  • Published Apr 27, 2021 2:35 AM GMT